- $172.35m
- $167.26m
- $109.43m
OptimizeRx Corporation reports results for the quarter ended June 30 - Earnings Summary
OptimizeRx Q2 revenue beats estimates on operating resilience; reaffirms outlook
OptimizeRx Corporation expected to post earnings of 12 cents a share - Earnings Preview
Brief: Optimizerx Corp - Enters Credit Agreement With Fifth Third Bank On May 7, 2026 - SEC Filing
OptimizeRx Q1 revenue beats analyst estimates
Brief: Optimizerx Launches Programmatic Access To Authenticated EHR Advertising At Scale
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:46 AM
NASDAQ RESUMED AT 09:41 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Optimizerx Corp Enters Amendment No. 4 To Financing Agreement- SEC Filing
OptimizeRx Q4 revenue stable, beats estimates
Brief: Optimizerx And Experian Collaborate To Improve Privacy-Safe Identity Resolution In Healthcare Marketing
OptimizeRx Q3 revenue beats estimates, raises 2025 revenue guidance
OptimizeRx Corp reports results for the quarter ended June 30 - Earnings Summary
Brief: OPTIMIZERx Q2 Revenue USD 29.2 Million Vs. IBES Estimate USD 22.3 Million
OptimizeRx Corp expected to post earnings of 2 cents a share - Earnings Preview